Why the study?
This study evaluated the Class III heart failure patient experience with pulmonary artery pressure monitoring over 24 months, including quality of life, illness perception, modality evaluation, and adherence.
Does pulmonary artery pressure (PAP) monitoring improve quality of life and sense of control in Class III heart failure patients?
Does pulmonary artery pressure (PAP) monitoring improve quality of life and sense of control in Class III heart failure patients?
Pulmonary artery pressure-guided management in Class III heart failure is associated with sustained improvements in patient-reported quality of life and sense of control over 2 years.
Answers are grounded in this paper and cite their sources.
Patient experiences with PAP monitoring in Class III HF remain hypothesis-generating; this cohort data leaves open effects on QoL, control, and adherence.
AIMS: This study investigated Class III heart failure patient experience with pulmonary artery pressure (PAP) monitoring over 24 months including (1) changes in reported quality of life (QoL), (2) changes in HF illness perception and sense of control (control), (3) patient evaluation of PAP-guided therapy as a modality and (4) behavioural adherence to remote monitoring. METHODS AND RESULTS: A 272 patient subgroup from the N = 1200 patient CardioMEMS™ Post-Approval Study completed 3 questionnaires including HF-related QoL, illness perception and control, and PAP therapy evaluation. Patient measurement frequency was also collected as a behavioural adherence index. Patient perception of illness was assessed via a general linear mixed model to account for all data available at all time points (n = 272). A paired analysis of patients with 24-month questionnaires (n = 135) was performed to further evaluate patients who completed follow-up. Patients reported significant improvement in overall QoL scores from baseline (44.5 ± 24.0) to 6 months (58.8 ± 25.2) which was maintained through 2 years (all P < 0.0001). Patients described their sense of control as strong (4.3 ± 0.9, 5 is strongly agree), positively evaluated PAP-guided therapy (4.1 ± 1.0, 5 is strongly agree), and 90% actively transmitted device data weekly with a significant reduction in patient perceived illness throughout 2 years of follow-up. CONCLUSIONS: Two-year follow up of the patient experience of PAP-guided therapy indicated that patients reported increased QoL, perceptions of control, device acceptability and continued remote monitoring over the 24 month follow-up. These results suggest that knowledge of PA pressures is associated with positive patient experience and engagement in HF care.
No takes yet. Share an insight, caveat, or question.
Rathman et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: